These contradictory trends are reinforced by changes we see in the market access stakeholders’ map: • Payers have an increased influence on physicians’ prescriptions. They scrutinize drugs ...

Maintain internal payer and stakeholder maps up-to-date: As new committees are being created and new stakeholders are becoming involved in drug evaluations, it will be important to monitor who is who.

“It is time to develop a joint strategy as a community, development stakeholders, quality regulators and TPHPA. After formulating this strategy we will present it to the public for review and ...